StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL – Free Report) in a research report report published on Monday morning. The brokerage issued a sell rating on the medical technology company’s stock.
Several other equities analysts have also recently issued reports on BIOL. Benchmark reaffirmed a “speculative buy” rating and set a $0.40 price objective on shares of BIOLASE in a report on Wednesday, October 2nd. Ascendiant Capital Markets decreased their price objective on shares of BIOLASE from $3.50 to $2.00 and set a “buy” rating on the stock in a research report on Tuesday, September 3rd.
View Our Latest Report on BIOLASE
BIOLASE Stock Performance
About BIOLASE
BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.
Featured Stories
- Five stocks we like better than BIOLASE
- The 3 Best Fintech Stocks to Buy Now
- Work and Play: Investing in the Rise of Bleisure Travel
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Top Dividend Stocks to Buy Now as Bond Yields Could Lower
- Overbought Stocks Explained: Should You Trade Them?
- SAP: AI Tailwinds Accelerating Enterprise Cloud Business
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.